Last quarter (Q4 2023), Cognition Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Cognition Therapeutics's net income was $-457.00K. See Cognition Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 50.72M	$ 50.72M	$ -43.55M	$ -28.60M	$ 6.55M	$ 4.67M
Operating Income	$ -50.72M	$ -50.72M	$ -43.55M	$ -28.60M	$ -6.55M	$ -4.67M
Net Non Operating Interest Income Expense	$ -27.00K	$ -27.00K	-	$ 895.00K	$ -1.75M	$ -1.02M
Other Income Expense	-	-	$ -22.22M	$ -17.86M	$ 464.00K	$ 849.00K
Pretax Income	$ -50.59M	$ -50.59M	$ -21.40M	$ -11.72M	$ -7.84M	$ -4.84M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	$ 22.22M	$ -2.24M	-	-
Net Income Common Stockholders	$ -25.79M	$ -25.79M	$ -21.40M	$ -16.25M	$ -12.07M	$ -8.76M
Basic EPS	$ -0.85	$ -0.86	$ -0.91	$ -3.13	$ -0.56	$ -0.41
Diluted EPS	$ -0.85	$ -0.86	$ -0.91	$ -3.13	$ -0.56	$ -0.41
Basic Average Shares	$ 120.12M	$ 30.03M	$ 23.64M	$ 5.19M	$ 21.37M	$ 21.37M
Diluted Average Shares	$ 120.12M	$ 30.03M	$ 23.64M	$ 5.19M	$ 21.37M	$ 21.37M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 50.72M	$ 50.72M	$ -43.55M	$ -28.60M	$ 6.55M	$ 4.67M
Net Income From Continuing And Discontinued Operation	$ -25.79M	$ -25.79M	$ -21.40M	$ -11.72M	$ -7.84M	$ -4.84M
Normalized Income	$ -28.53M	$ -40.13M	-	-	$ -7.91M	$ -4.60M
Interest Expense	-	-	-	-	$ 1.75M	$ 1.02M
EBIT	$ -50.56M	$ -50.57M	$ -21.40M	$ -11.72M	$ -6.09M	$ -3.82M
EBITDA	$ -50.30M	$ -50.31M	$ -21.16M	$ -11.24M	$ -5.99M	$ -3.74M

Currency in USD

Cognition Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing